Jackson Square Partners LLC lowered its position in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 3.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,864,733 shares of the biopharmaceutical company’s stock after selling 76,293 shares during the quarter. Jackson Square Partners LLC’s holdings in Portola Pharmaceuticals were worth $64,706,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Portola Pharmaceuticals by 0.4% in the 4th quarter. BlackRock Inc. now owns 5,326,939 shares of the biopharmaceutical company’s stock worth $103,982,000 after buying an additional 19,532 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Portola Pharmaceuticals by 41.7% in the 1st quarter. William Blair Investment Management LLC now owns 4,154,870 shares of the biopharmaceutical company’s stock worth $144,174,000 after buying an additional 1,222,057 shares in the last quarter. Fiera Capital Corp acquired a new position in Portola Pharmaceuticals in the 1st quarter worth $53,590,000. Brandywine Global Investment Management LLC lifted its holdings in Portola Pharmaceuticals by 11.8% in the 4th quarter. Brandywine Global Investment Management LLC now owns 834,967 shares of the biopharmaceutical company’s stock worth $16,299,000 after buying an additional 87,999 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Portola Pharmaceuticals by 3.4% in the 1st quarter. Northern Trust Corp now owns 830,822 shares of the biopharmaceutical company’s stock worth $28,831,000 after buying an additional 26,943 shares in the last quarter.
A number of equities analysts have commented on PTLA shares. BidaskClub upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. ValuEngine upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a report on Thursday, April 4th. Oppenheimer set a $42.00 price objective on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 12th. Finally, Cowen reiterated a “buy” rating on shares of Portola Pharmaceuticals in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $42.29.
In other news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $34.45, for a total value of $172,250.00. Following the sale, the director now owns 14,000 shares in the company, valued at approximately $482,300. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Mardi Dier sold 40,486 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $37.39, for a total transaction of $1,513,771.54. Following the completion of the sale, the chief financial officer now owns 66,733 shares in the company, valued at approximately $2,495,146.87. The disclosure for this sale can be found here. Corporate insiders own 4.50% of the company’s stock.
Shares of Portola Pharmaceuticals stock traded down $0.98 during trading on Wednesday, reaching $25.29. The company had a trading volume of 38,819 shares, compared to its average volume of 1,305,970. The firm has a market cap of $1.75 billion, a PE ratio of -5.11 and a beta of 2.43. The company has a debt-to-equity ratio of 5.15, a quick ratio of 4.77 and a current ratio of 4.81. Portola Pharmaceuticals Inc has a fifty-two week low of $14.81 and a fifty-two week high of $44.25.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.02). The business had revenue of $22.17 million for the quarter, compared to analyst estimates of $20.60 million. Portola Pharmaceuticals had a negative net margin of 618.46% and a negative return on equity of 238.48%. The company’s revenue for the quarter was up 233.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.28) EPS. On average, equities analysts predict that Portola Pharmaceuticals Inc will post -4.13 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thelincolnianonline.com/2019/06/12/portola-pharmaceuticals-inc-nasdaqptla-holdings-reduced-by-jackson-square-partners-llc.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Recommended Story: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.